Form 4: Kura Oncology COO Sells Shares to Cover Taxes

Kura Oncology's Chief Operating Officer, Kathleen Ford, sold 1,817 shares of common stock to cover taxes related to a vesting of restricted stock units.

Summary

• Kathleen Ford, the Chief Operating Officer of Kura Oncology, sold 1,817 shares of common stock on January 28, 2025.
• The sale was executed at a price of $7.8719 per share.
• This transaction was a sell-to-cover for taxes associated with the vesting of a restricted stock unit (RSU) that was granted on January 26, 2022.
• Following the transaction, Ms. Ford directly owns 21,367 shares of Kura Oncology common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, a routine transaction for tax purposes, and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for corporate executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice among publicly traded companies, particularly when executives receive equity compensation.
• The sale of 1,817 shares is relatively small compared to the total number of shares outstanding for Kura Oncology, and is not unusual for an executive's tax obligations.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but is unlikely to be significant.

Key Dates

Keywords

Kura Oncology, Kathleen Ford, stock sale, Form 4, insider trading, restricted stock unit, RSU, tax obligations